

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy [ID690]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No potential equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

Two potential equality issues were identified in the academic report.

Firstly, the ERG described how it was advised by a clinical expert that ethnic minority patients' access to biological treatment is lower than white British patients'. The Committee considered that lack of uptake of NICE-recommended treatments by any minority group was an implementation issue and could not be addressed in a NICE technology appraisal.
--

Secondly, another clinical expert told the ERG that having surgery or creating a stoma may be problematic for some people from some cultures and backgrounds and that a treatment that could delay or reduce the risk of such procedures could be important in terms of equity. The Committee heard from the clinical and patients experts that, in general, people with Crohn's disease preferred to manage their condition medically rather than surgically, and therefore considered that this did not represent an equality issue.
--

No other potential equality issues were identified in the submissions or expert statements.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues have been identified by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

The Committee's considerations of equality issues are described in

section 4.20 of the appraisal consultation document.

Approved by Associate Director (name): Janet Robertson.....

Date: 16/12/2014

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

Two potential equality issues were raised during consultation. The Committee was aware that surgery can affect fertility and has particular issues for people following certain religious practices. The Committee considered that this did not represent an equality issue because it had heard from the clinical and patients experts that, in general, people with Crohn's disease preferred to manage their condition medically rather than surgically. The Committee considered that there were no equality issues associated with age because vedolizumab brought treatment benefits to adults of all ages.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of

the disability?
No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

5. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
The Committee's considerations of equality issues have been described in section 4.26 of the FAD.

Approved by Centre or Programme Director (name): Meindert Boysen.....

Date: 24th June 2015

Final Appraisal Determination

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

[Insert response here]

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

[Insert response here]

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

[Insert response here]

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

[Insert response here]

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

[Insert response here]

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

[Insert response here]

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

[Insert response here]

Approved by Programme Director (name):

Date: [xx/xx/year]